Atomwise
Mark Sabat is an experienced professional in the field of medicinal chemistry, currently serving as the Director of Medicinal Chemistry at Turning Point Therapeutics since January 2022. Prior to this role, Mark held various positions at Takeda, including Associate Director of GI Chemistry and Principal Scientist in Medicinal Chemistry from August 2011 to January 2022, as well as Senior Scientist from August 2006 to June 2011.
This person is not in any offices
Atomwise
5 followers
Atomwise patented the first deep learning technology for structure-based small molecule drug discovery. This AI technology harnesses millions of data points and thousands of protein structures to solve problems that a human chemist would take many lifetimes to solve. They've partnered with some of the world’s largest pharmaceutical and agrochemical companies, and with more than 50 leading academic institutions and hospitals, to tackle the challenges of discovering and developing better drugs and chemicals.